Company Filing History:
Years Active: 1996-2003
Title: Innovations of Hans-Juergen Gruss
Introduction
Hans-Juergen Gruss is a notable inventor based in Bainbridge Island, WA (US). He has made significant contributions to the field of biotechnology, particularly in the development of polypeptides and their applications in cancer treatment. With a total of six patents to his name, Gruss has established himself as a key figure in his area of expertise.
Latest Patents
One of his latest patents involves the CD30 ligand, which discloses a polypeptide (CD30-L) along with DNA sequences, vectors, and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on various cell types, including Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, and adult T-cell leukemia (T-ALL) cells. These CD30-L polypeptides serve as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor. Another patent focuses on CD30 ligand oligomers and polypeptides, reiterating the importance of CD30-L in targeting malignant cell types.
Career Highlights
Gruss is currently associated with Immunex Corporation, where he continues to innovate and contribute to advancements in medical science. His work has been instrumental in developing therapies that target specific cancer cells, thereby improving treatment outcomes for patients.
Collaborations
Throughout his career, Gruss has collaborated with notable colleagues such as Raymond G. Goodwin and Craig A. Smith. These partnerships have fostered a collaborative environment that enhances research and development efforts in the field.
Conclusion
Hans-Juergen Gruss is a distinguished inventor whose work in biotechnology has led to significant advancements in cancer treatment. His innovative patents and collaborations reflect his commitment to improving healthcare through scientific research.